Answer
Rifampicin, a potent CYP3A4 inducer, reduced median erlotinib exposure (AUC) by 69% when given at 600 mg orally once daily for seven days with erlotinib; concomitant use should be avoided.
Sources for this answer
- Tarceva 25 mg, 100 mg & 150 mg Film-coated TabletsRoche Products Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 11Document updated
Sources checked